Chen, Kuen-Feng <br/><br/>
Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity.  [electronic resource] 

 -  Bioorganic & medicinal chemistry  Oct 2012 
 - 6144-53 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1464-3391 
<br/><br/><label>Standard No.: </label>10.1016/j.bmc.2012.08.039  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Down-Regulation--drug effects<br/>ErbB Receptors--antagonists & inhibitors<br/>Erlotinib Hydrochloride<br/>Humans<br/>Protein Phosphatase 2--antagonists & inhibitors<br/>Pyrimidines--chemistry<br/>Quinazolines--chemical synthesis<br/>Structure-Activity Relationship